>
Bionano Genomics Inc logo

BNGOU - Bionano Genomics Inc Share Price

$7.55 0.2  2.4%

Sector
Healthcare
Size
Market Cap £n/a
Enterprise Value £n/a
Revenue £n/a
Position in Universe th / 6847
Bullish
Bearish
Unlock BNGOU Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 01st Jan 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, BioNanoGenomics Inc revenues decreased 16% to $8.5M. Net lossincreased 38% to $41.1M. Revenues reflect Asia Pacificsegment decrease of 42% to $851K, Northern America segmentdecrease of 11% to $4.5M. Higher net loss reflects Selling,general and administrative - Ba increase of 48% to $28.3M(expense), Research and development - Balancing valincrease of 12% to $9.9M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

BNGOU Revenue Unlock BNGOU Revenue

Net Income

BNGOU Net Income Unlock BNGOU Revenue

Normalised EPS

BNGOU Normalised EPS Unlock BNGOU Revenue

PE Ratio Range

BNGOU PE Ratio Range Unlock BNGOU Revenue

Dividend Yield Range

BNGOU Dividend Yield Range Unlock BNGOU Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
BNGOU EPS Forecasts Unlock BNGOU Revenue
Profile Summary

Bionano Genomics, Inc. is a life sciences instrumentation company in the genome analysis space. The Company develops and markets the Saphyr system. The Company’s products include Sequencing for Discovery Research and Cytogenetics. Cytogenetics provide a clinical diagnosis, cytogenetic tests detect known variations that are linked to specific diseases or therapeutic responses. Saphyr system is platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. Sequencing for Discovery Research is primarily used to find single nucleotide variations responsible for disease or therapeutic response. The Company’s subsidiary, Lineagen, Inc., provides molecular diagnostics services for individuals.

Directors
Last Annual January 1st, 1970
Last Interim January 1st, 1970
Incorporated January 24, 2003
Public Since August 1, 2018
No. of Shareholders: 90
No. of Employees: 147
Sector Healthcare
Industry Healthcare Equipment & Supplies
Index
Exchange NASDAQ Capital Market
Shares in Issue
Free Float (0.0%)
Eligible for
× ISAs
SIPPs
BNGOU Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.